Edwards Lifesciences (EW) Long-Term Deferred Tax (2009 - 2026)

Edwards Lifesciences has reported Long-Term Deferred Tax for 18 years, with the latest figure at $911.8 million in Q2 2026.

• On a quarterly basis, Long-Term Deferred Tax fell 15.74% year-over-year to $911.8 million in Q2 2026; TTM through Jun 2026 was $911.8 million, a 15.74% decrease from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 14.72% from the prior year.
• Long-Term Deferred Tax was $911.8 million for Q2 2026 at Edwards Lifesciences, down from $1.1 billion in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $1.1 billion in Q4 2025, with the low at $294.9 million in Q1 2022.
• Average Long-Term Deferred Tax over 5 years is $768.8 million, with a median of $804.6 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2026: Long-Term Deferred Tax soared 98.54% in 2023, then slipped 15.74% in 2026.
• Over 5 years, Long-Term Deferred Tax stood at $484.0 million in 2022, then surged by 54.83% to $749.4 million in 2023, then jumped by 32.39% to $992.1 million in 2024, then grew by 14.72% to $1.1 billion in 2025, then declined by 19.88% to $911.8 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $911.8 million (Q2 2026), $1.1 billion (Q1 2026), and $1.1 billion (Q4 2025), per Business Quant data.